

Valter Gattei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/446923/publications.pdf>

Version: 2024-02-01

325
papers

11,491
citations

36303

51
h-index

38395

95
g-index

327
all docs

327
docs citations

327
times ranked

9931
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	8.5	565
2	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	1.4	420
3	Mutations of <i>NOTCH1</i> are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-529.	1.4	394
4	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	8.5	363
5	Mutations of the <i>SF3B1</i> splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908.	1.4	342
6	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	1.4	316
7	Clinical impact of small <i>TP53</i> mutated subclones in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 2139-2147.	1.4	302
8	The Prognostic Value of <i>TP53</i> Mutations in Chronic Lymphocytic Leukemia Is Independent of <i>Del17p13</i> : Implications for Overall Survival and Chemorefractoriness. <i>Clinical Cancer Research</i> , 2009, 15, 995-1004.	7.0	284
9	Disruption of <i>BIRC3</i> associates with fludarabine chemorefractoriness in <i>TP53</i> wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2854-2862.	1.4	257
10	Relevance of <i>CD49d</i> protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	1.4	226
11	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	1.4	208
12	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2008, 142, 202-215.	2.5	206
13	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
14	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	7.0	189
15	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173
16	Clinical significance of <i>ZAP-70</i> protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	1.4	171
17	<i>CD49d</i> Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904.	1.6	162
18	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002, 99, 856-862.	1.4	155

#	ARTICLE	IF	CITATIONS
19	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.9	153
20	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009, 146, 64-75.	2.5	136
21	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	1.4	126
22	CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. <i>Journal of Immunology</i> , 2015, 195, 4555-4563.	0.8	125
23	The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 1783-1789.	7.2	117
24	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	1.4	113
25	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997, 89, 2048-2059.	1.4	110
26	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. <i>British Journal of Haematology</i> , 2002, 117, 366-372.	2.5	106
27	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
28	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	7.0	92
29	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	3.5	91
30	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	4.1	86
31	The KrÄppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	7.2	84
32	Hyaluronanâ€CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. <i>Journal of Cell Biology</i> , 2002, 158, 1133-1144.	5.2	83
33	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. <i>Blood</i> , 2009, 113, 4300-4308.	1.4	83
34	5-Aza-2â€deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003, 101, 4644-4646.	1.4	78
35	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2012, 26, 1301-1312.	7.2	78
36	The miR-17âˆ“92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. <i>Leukemia</i> , 2012, 26, 1584-1593.	7.2	77

#	ARTICLE	IF	CITATIONS
37	Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1).. Journal of Cell Biology, 1992, 116, 437-447.	5.2	76
38	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia, 2016, 30, 182-189.	7.2	74
39	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 1575-1579.	3.5	72
40	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	2.8	67
41	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	8.5	65
42	Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia, 2015, 29, 406-414.	7.2	64
43	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
44	Comprehensive characterization of IGHV3-21 ⁺ expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood, 2007, 109, 2989-2998.	1.4	62
45	Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. British Journal of Haematology, 2008, 143, 532-536.	2.5	58
46	Interactions Between Tissue Fibroblasts in Lymph Nodes and Hodgkin/Reed-Sternberg Cells. Leukemia and Lymphoma, 2004, 45, 1731-1739.	1.3	57
47	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 2007, 21, 965-972.	7.2	57
48	Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. American Journal of Pathology, 2002, 160, 585-596.	3.8	56
49	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. Blood, 1997, 89, 3787-3794.	1.4	55
50	<i>IGLV3-21[*]01</i> is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4320-4327.	7.1	55
51	Analysis of IgVH gene mutations in B-cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42.	2.5	54
52	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	3.5	53
53	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia, 2017, 31, 2407-2415.	7.2	52
54	Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. World Journal of Hepatology, 2016, 8, 107.	2.0	52

#	ARTICLE	IF	CITATIONS
55	CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. <i>Leukemia</i> , 2006, 20, 523-525.	7.2	51
56	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	1.4	51
57	The MYCⁱ/miR-17-92</i> axis in lymphoproliferative disorders: A common pathway with therapeutic potential. <i>Oncotarget</i> , 2015, 6, 19381-19392.	1.8	51
58	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie " GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784.	0.9	50
59	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383.	2.8	50
60	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363.	4.1	49
61	The role of eosinophils in the pathobiology of Hodgkin's disease. <i>Annals of Oncology</i> , 1997, 8, S89-S96.	1.2	48
62	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	1.4	48
63	Genomic profiling of Richter's syndrome: recurrent lesions and differences with ⁱde novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67.	1.7	46
64	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752.	4.1	45
65	p27^{kip1} controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13916-13921.	7.1	45
66	Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 81-90.	1.5	45
67	Expression of Mutated ⁱIGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	7.0	44
68	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	6.0	43
69	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249.	3.3	42
70	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	4.4	41
71	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	7.2	41
72	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	2.5	40

#	ARTICLE	IF	CITATIONS
73	In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. <i>Hematological Oncology</i> , 1989, 7, 287-293.	1.7	39
74	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
75	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	1.5	38
76	CD40/CD40 Ligand Interactions in Normal, Reactive and Malignant Lympho-Hematopoietic Tissues. <i>Leukemia and Lymphoma</i> , 1997, 24, 393-422.	1.3	36
77	New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. <i>PLoS ONE</i> , 2013, 8, e74216.	2.5	34
78	Genetic characterization of p27 ^{kip1} and stathmin in controlling cell proliferation in vivo. <i>Cell Cycle</i> , 2014, 13, 3100-3111.	2.6	34
79	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
80	Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e135-e138.	3.5	34
81	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38 ⁺ CD49d ⁺ chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2010, 150, 111-112.	2.5	33
82	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
83	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. <i>Leukemia</i> , 2015, 29, 356-368.	7.2	33
84	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	1.4	33
85	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
86	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. <i>Haematologica</i> , 2012, 97, 279-287.	3.5	32
87	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. <i>Seminars in Hematology</i> , 2014, 51, 168-176.	3.4	32
88	CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. <i>Experimental Hematology</i> , 2002, 30, 1283-1292.	0.4	31
89	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- κ B pathways. <i>Leukemia</i> , 2018, 32, 654-662.	7.2	31
90	In vitro and in vivo effects of 2-deoxycoformycin (Pentostatin) on tumour cells from human β 2-microglobulin ⁺ T-cell malignancies. <i>British Journal of Haematology</i> , 2000, 110, 188-196.	2.5	30

#	ARTICLE	IF	CITATIONS
91	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	4.1	30
92	Bâ€cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	2.5	30
93	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	1.7	30
94	Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. <i>Leukemia</i> , 2018, 32, 685-693.	7.2	29
95	Expression and Localization of the Homeodomain-Containing Protein HEX in Human Thyroid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1376-1383.	3.6	29
96	CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. <i>Seminars in Cancer Biology</i> , 2010, 20, 416-423.	9.6	28
97	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	2.5	28
98	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 3006-3010.	5.1	28
99	Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. <i>Haematologica</i> , 2016, 101, e99-e102.	3.5	28
100	Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 7104.	3.3	28
101	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53^{wildâ€™type} CLL with a poor cytotoxic response to Nutlinâ€3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	2.5	27
102	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , 2014, 124, 3831-3833.	1.4	27
103	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	2.5	26
104	CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylationâ€dependent and â€independent mechanisms. <i>British Journal of Haematology</i> , 2015, 169, 286-289.	2.5	26
105	Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases. <i>Diseases (Basel)</i> , Tj ETQq1 1 0.784314 rgBT /Overlock	2.5	26
106	In vitro structural and functional relationships between preosteoclastic and bone endothelial cells: A juxtacrine model for migration and adhesion of osteoclast precursors. <i>Journal of Cellular Physiology</i> , 1995, 162, 199-212.	4.1	25
107	CD26 Expression Correlates with a Reduced Sensitivity to 2â€Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas. <i>Clinical Cancer Research</i> , 2004, 10, 508-520.	7.0	25
108	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25

#	ARTICLE	IF	CITATIONS
109	Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8884-8888.	7.1	24
110	In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay. Hematological Oncology, 1989, 7, 243-253.	1.7	23
111	Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?. Leukemia, 2005, 19, 1490-1492.	7.2	23
112	Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. Journal of Cellular Physiology, 2005, 202, 474-477.	4.1	23
113	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 5566-5575.	7.0	23
114	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. Cells, 2021, 10, 98.	4.1	23
115	Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. British Journal of Haematology, 1999, 104, 152-162.	2.5	22
116	Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. British Journal of Haematology, 2002, 118, 1055-1064.	2.5	22
117	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2014, 7, 79.	17.0	22
118	Hepatitis C Virus-Associated Non-Hodgkin Lymphomas. Clinics in Liver Disease, 2017, 21, 499-515.	2.1	22
119	<i>NOTCH1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British Journal of Haematology, 2018, 182, 597-602.	2.5	22
120	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. Cancers, 2020, 12, 894.	3.7	22
121	Follicular Lymphoma of Compartmentalized Small Cleaved Center Cells and Mantle Zone Lymphocytes: Evidence for a Common Derivation. American Journal of Clinical Pathology, 1992, 98, 437-448.	0.7	21
122	Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms. American Journal of Pathology, 1999, 155, 2029-2041.	3.8	21
123	Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. British Journal of Haematology, 2008, 141, 734-736.	2.5	21
124	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Journal of Translational Medicine, 2012, 10, 18.	4.4	21
125	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. Haematologica, 2018, 103, 849-856.	3.5	21
126	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	7.2	21

#	ARTICLE	IF	CITATIONS
127	Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. <i>Autoimmunity Reviews</i> , 2020, 19, 102589.	5.8	21
128	CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001, 508, 418-422.	2.8	20
129	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	1.7	20
130	Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. <i>British Journal of Haematology</i> , 2020, 191, 775-783.	2.5	20
131	EXPRESSION OF NATURAL KILLER ANTIGENS IN A SUBSET OF "ON-T. NON-B LYMPHOMA/LEUKAEMIA WITH HISTIOCYTIC FEATURES". <i>British Journal of Haematology</i> , 1990, 76, 444-448.	2.5	19
132	Hodgkin's disease: A disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht, Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 542 T</i>	0.7	19
133	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999, 105, 225-240.	2.5	19
134	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	4.4	19
135	Promoter methylation patterns in Richter syndrome affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 194-204.	2.5	19
136	Hepatitis B virus-related cryoglobulinemic vasculitis. The role of antiviral nucleoside analogues: a review. <i>Journal of Internal Medicine</i> , 2019, 286, 290-298.	6.0	19
137	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	3.3	19
138	Normalizing Complementary DNA by Quantitative Reverse Transcriptase-Polymerase Chain Reaction of Î2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 98-109.	2.1	19
139	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 42398-42413.	1.8	19
140	Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. <i>Leukemia and Lymphoma</i> , 2006, 47, 885-889.	1.3	18
141	Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	3.5	18
142	Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. <i>Medical Oncology</i> , 2018, 35, 118.	2.5	18
143	VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2206.	4.1	18
144	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. <i>Drugs of Today</i> , 2016, 52, 249.	1.1	18

#	ARTICLE	IF	CITATIONS
145	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. <i>Oncotarget</i> , 2015, 6, 12048-12060.	1.8	18
146	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015, 6, 19102-19117.	1.8	18
147	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2004, 89, 1468-75.	3.5	18
148	Epigenetic Immunomodulation of Hematopoietic Malignancies. <i>Seminars in Oncology</i> , 2005, 32, 503-510.	2.2	17
149	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. <i>Journal of Immunological Methods</i> , 2005, 305, 20-32.	1.4	17
150	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , 2006, 30, 1197-1199.	0.8	17
151	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. <i>Immunology Letters</i> , 2011, 134, 137-144.	2.5	17
152	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3323-3334.	1.9	17
153	TLR9 signaling defines distinct prognostic subsets in CLL. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 371.	3.0	17
154	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>Nano Research</i> , 2016, 9, 537-548.	10.4	17
155	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	7.2	17
156	COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 712-714.	1.7	17
157	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011, 118, 1359-1359.	1.4	17
158	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106.	1.3	16
159	Competitive reverse-transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. <i>Biochemical Journal</i> , 1997, 325, 565-567.	3.7	15
160	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	3.5	15
161	Reducing chemotherapy-associated toxicity in elderly cancer patients. <i>Cancer Treatment Reviews</i> , 1996, 22, 223-244.	7.7	14
162	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012, 97, 849-853.	3.5	14

#	ARTICLE	IF	CITATIONS
163	Clinical significance of c.7544â€7545 del<scp>CT </scp><i><scp>NOTCH</scp>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	2.5	14
164	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	17.0	14
165	A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. <i>Journal of Pathology</i> , 2002, 197, 256-263.	4.5	13
166	Analysis of the <i>REL</i>, <i>BCL11A</i>, and <i>MYCN</i> protoâ€oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 541-544.	4.1	13
167	A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. <i>Vox Sanguinis</i> , 2010, 98, 172-180.	1.5	13
168	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 2049-2058.	3.5	13
169	Minimal residual disease (MRD) in nonâ€Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	1.7	13
170	Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998, 77, 207-210.	1.8	12
171	Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118895.	5.2	12
172	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021, 253, 234-245.	4.5	12
173	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. <i>Blood</i> , 2019, 134, 480-480.	1.4	12
174	A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2016, 7, 26346-26360.	1.8	12
175	<i>>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	3.5	12
176	CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. <i>Leukemia and Lymphoma</i> , 1999, 35, 21-35.	1.3	11
177	Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia. <i>Matrix Biology</i> , 2007, 26, 473-484.	3.6	11
178	APE/Ref-1 makes fine-tuning of CD40-induced B cell proliferation. <i>Molecular Immunology</i> , 2008, 45, 3731-3739.	2.2	11
179	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementary Table). <i>Current Cancer Drug Targets</i> , 2009, 9, 510-518.	1.6	11
180	Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. <i>Investigational New Drugs</i> , 2011, 29, 392-395.	2.6	11

#	ARTICLE	IF	CITATIONS
181	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. <i>Blood</i> , 2012, 119, 2106-2109.	1.4	11
182	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	3.5	11
183	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 659-668.	1.6	11
184	Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 107-114.	0.8	11
185	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002, 117, 59-69.	2.5	10
186	Reply to Pittner et al.. <i>Leukemia</i> , 2006, 20, 528-529.	7.2	10
187	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <i>American Journal of Hematology</i> , 2010, 85, 619-622.	4.1	10
188	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. <i>Leukemia</i> , 2014, 28, 705-708.	7.2	10
189	Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. <i>Leukemia</i> , 2019, 33, 1278-1302.	7.2	10
190	Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2 has prognostic value in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1045-1050.	2.5	10
191	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
192	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. <i>British Journal of Haematology</i> , 2022, 198, 1016-1022.	2.5	10
193	Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 123-126.	2.1	9
194	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. <i>Journal of Translational Medicine</i> , 2006, 4, 11.	4.4	9
195	CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. <i>Future Oncology</i> , 2008, 4, 355-358.	2.4	9
196	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	1.3	9
197	Low-dose radiotherapy in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 472-479.	1.7	9
198	Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	2.5	9

#	ARTICLE	IF	CITATIONS
199	Transcriptomics and Immunological Analyses Reveal a Pro-Angiogenic and Anti-Inflammatory Phenotype for Decidual Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1604.	4.1	9
200	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	1.7	9
201	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	7.2	8
202	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	3.5	8
203	Hepatitis C virus-related cryoglobulinemic vasculitis. <i>Minerva Medica</i> , 2021, 112, 175-187.	0.9	8
204	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
205	KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 666.	3.7	8
206	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483.	7.2	7
207	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	6.2	7
208	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	1.4	7
209	Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. <i>Blood Advances</i> , 2021, 5, 4890-4900.	5.2	7
210	Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy. <i>Hematological Oncology</i> , 2021, 39, 439-447.	1.7	6
211	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019, 134, 124-124.	1.4	6
212	The role of interleukin-3 and stem cell factor in classical Hodgkin disease. <i>Blood</i> , 2003, 101, 376-376.	1.4	5
213	Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor. <i>Vox Sanguinis</i> , 2008, 94, 342-350.	1.5	5
214	Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. <i>Human Pathology</i> , 2009, 40, 1045-1049.	2.0	5
215	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414.	3.5	5
216	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5

#	ARTICLE	IF	CITATIONS
217	Recent news in the treatment of hepatitis B virus-related cryoglobulinemic vasculitis. <i>Minerva Medica</i> , 2020, 111, 566-572.	0.9	5
218	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.	1.4	5
219	Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. <i>Cancers</i> , 2022, 14, 2997.	3.7	5
220	Interleukin-3 Receptors in Hodgkin's Disease. <i>American Journal of Pathology</i> , 2003, 162, 355-357.	3.8	4
221	Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. <i>Methods in Molecular Biology</i> , 2019, 1881, 101-112.	0.9	4
222	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	7.2	4
223	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	1.4	4
224	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 251-252.	1.4	3
225	How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2009, 27, 186-189.	1.7	3
226	<i>ARHGDI1</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	2.5	3
227	Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. <i>Digestive and Liver Disease</i> , 2015, 47, 613-616.	0.9	3
228	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016, 30, 513-517.	7.2	3
229	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. <i>Hematological Oncology</i> , 2019, 37, 628-633.	1.7	3
230	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704.	1.7	3
231	Hepatitis C virus-associated non-Hodgkin lymphomas: the endless history. <i>Minerva Medica</i> , 2021, 112, 215-227.	0.9	3
232	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
233	Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. , 2019, , .		3
234	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569.	1.4	3

#	ARTICLE	IF	CITATIONS
235	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397.	1.4	3
236	Elastin Microfibril Interfacer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	1.7	3
237	Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
238	Integrin Signaling Shaping BTK-Inhibitor Resistance. <i>Cells</i> , 2022, 11, 2235.	4.1	3
239	Proliferation and cell loss of human leukemic cell subpopulations in liquid culture. <i>Experientia</i> , 1988, 44, 245-247.	1.2	2
240	Differential sensitivity to (dl)-5-methyltetrahydrofolate of normal CFU-GM and HL-60 cells. <i>Leukemia Research</i> , 1989, 13, 595-598.	0.8	2
241	Induction of Differentiation of HL-60 Cells Along the Monocytic Pathway by 5-Methyltetrahydrofolate. <i>Journal of Chemotherapy</i> , 1989, 1, 359-364.	1.5	2
242	In Vitro Cellular Systems for Studying OC Function and Differentiation: Primary OC Cultures and the FLG 29.1 Model. , 1996, 2, 277-306.		2
243	Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. <i>Aids</i> , 2004, 18, 1859-1861.	2.2	2
244	A case of SRSF2 mutation in chronic lymphocytic leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 11-14.	0.4	2
245	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502.	7.2	2
246	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4396-4396.	1.4	2
247	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	1.4	2
248	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3031-3031.	1.4	2
249	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	1.4	2
250	CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 672-672.	1.4	2
251	The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2009, 114, 1252-1252.	1.4	2
252	Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. <i>Infezioni in Medicina</i> , 2014, 22, 337-41.	1.1	2

#	ARTICLE	IF	CITATIONS
253	<i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	2.5	1
254	Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL Letter. <i>Clinical Cancer Research</i> , 2016, 22, 3410-3411.	7.0	1
255	Error-Prone DNA Polymerases <i>iota</i> and <i>beta</i> Are Over-Expressed in B-CLL Cells: Correlation with Specific IgVH Point-Mutations and Implication for the Pathogenesis of Intraclonal IgVH Diversification.. <i>Blood</i> , 2004, 104, 950-950.	1.4	1
256	Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2011, 118, 3906-3906.	1.4	1
257	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , 2012, 120, 929-929.	1.4	1
258	Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 116-116.	1.4	1
259	Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1370-1370.	1.4	1
260	BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrnas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4495-4495.	1.4	1
261	Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors. <i>Blood</i> , 2014, 124, 5668-5668.	1.4	1
262	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	1.4	1
263	Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 477-477.	1.4	1
264	ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2004, 104, 2806-2806.	1.4	1
265	Molecular, Phenotypic and Clinical Predictors of Richter Syndrome (RS) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 3086-3086.	1.4	1
266	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. <i>Blood</i> , 2010, 116, 2425-2425.	1.4	1
267	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	1.4	1
268	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 295-295.	1.4	1
269	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. <i>Blood</i> , 2016, 128, 4358-4358.	1.4	1
270	CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14039-e14039.	1.6	1

#	ARTICLE	IF	CITATIONS
271	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPi) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485.	1.4	1
272	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
273	Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
274	Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium. <i>Experientia</i> , 1988, 44, 903-906.	1.2	0
275	The transforming growth factor-beta in the regulation of normal and leukemic myelopoiesis. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1990, 2, 385-398.	0.7	0
276	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0
277	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S11-S12.	0.4	0
278	Regulation of HIF-1 \pm in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.4	0
279	TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?. <i>Clinical Cancer Research</i> , 2021, 27, 4462-4464.	7.0	0
280	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021, 5, e639.	2.7	0
281	Mutational Status of IgVH Genes in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Prognosis: Percent Mutations or Evaluation of Antigen-Driven Selection?. <i>Blood</i> , 2005, 106, 2106-2106.	1.4	0
282	Gene Expression Profiling (GEP) of CD38-Expressing/Unmutated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells by Using a Statistical Approach Suitable for Analysis of Unbalanced Datasets.. <i>Blood</i> , 2006, 108, 2089-2089.	1.4	0
283	Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. <i>Blood</i> , 2007, 110, 4696-4696.	1.4	0
284	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	1.4	0
285	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008, 112, 778-778.	1.4	0
286	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578.	1.4	0
287	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , 2010, 116, 3601-3601.	1.4	0
288	Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3574-3574.	1.4	0

#	ARTICLE	IF	CITATIONS
289	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. Blood, 2010, 116, 2951-2951.	1.4	0
290	Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2692-2692.	1.4	0
291	Abstract 1542: CD38 is physically associated with CD49d and enhances CD49d-mediated adhesion of B-Cell chronic lymphocytic leukemia cells. , 2011, , .		0
292	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. Blood, 2011, 118, 2845-2845.	1.4	0
293	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2870-2870.	1.4	0
294	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4581-4581.	1.4	0
295	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. Blood, 2012, 120, 930-930.	1.4	0
296	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. Blood, 2012, 120, 1772-1772.	1.4	0
297	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 712-712.	1.4	0
298	Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. Blood, 2013, 122, 870-870.	1.4	0
299	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0
300	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 1978-1978.	1.4	0
301	Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. Blood, 2015, 126, 1708-1708.	1.4	0
302	The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1720-1720.	1.4	0
303	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 1718-1718.	1.4	0
304	Targeted Nanoparticles for the Delivery of Antagomir17: New Approach for the Treatment of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 5293-5293.	1.4	0
305	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. Blood, 2015, 126, 701-701.	1.4	0
306	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4367-4367.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 3204-3204.	1.4	0
308	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	1.4	0
309	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.	1.4	0
310	HIF-1 α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	1.4	0
311	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.	1.4	0
312	Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma. , 2018, , .		0
313	The VLA-4 Integrin Is Constitutively Activated in a Subset of CD49d-Expressing CLL: A Relationship with the Autonomous BCR-Mediated Signaling?. <i>Blood</i> , 2018, 132, 5531-5531.	1.4	0
314	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944.	1.4	0
315	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. <i>Blood</i> , 2018, 132, 1838-1838.	1.4	0
316	Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 945-945.	1.4	0
317	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Blood</i> , 2018, 132, 2890-2890.	1.4	0
318	Serum IgM/Fc μ r Interactions Inhibit BCR Signaling and Influence the Clinical Course of CLL. <i>Blood</i> , 2018, 132, 4409-4409.	1.4	0
319	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. <i>Blood</i> , 2018, 132, 3113-3113.	1.4	0
320	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	1.4	0
321	Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA). <i>Blood</i> , 2019, 134, 1744-1744.	1.4	0
322	BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 1730-1730.	1.4	0
323	The VLA-4 Integrin Is Constitutively Activated in a Fraction of CD49d-Expressing Chronic Lymphocytic Leukemia Via Autonomous BCR-Mediated Signaling. <i>Blood</i> , 2019, 134, 849-849.	1.4	0
324	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. <i>Blood</i> , 2020, 136, 46-47.	1.4	0